Sandoz Group (OTCMKTS:SDZNY) Stock Price Down 1.8% - Should You Sell?

Key Points

• Sandoz Group AG's stock price fell by 1.8% on Tuesday, trading as low as $59.28 and closing at $59.43, with a significant drop in trading volume of 40% from the average.
• Jefferies Financial Group downgraded the stock from a "strong-buy" to a "hold" rating, contributing to the stock's current average rating of "Hold" by analysts.
• The company, which specializes in generic pharmaceuticals and biosimilars, has a quick ratio of 0.82 and a current ratio of 1.29, indicating potential financial challenges.

Shares of Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) dropped 1.8% during trading on Tuesday . The stock traded as low as $59.28 and last traded at $59.43. Approximately 14,355 shares changed hands during trading, a decline of 40% from the average daily volume of 23,988 shares. The stock had previously closed at $60.53.

Analysts Set New Price Targets

Separately, Jefferies Financial Group cut shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 8th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold".

Sandoz Group Trading Down 1.8%

The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62. The stock's fifty day simple moving average is $59.89 and its 200-day simple moving average is $52.38.

Sandoz Group Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.